Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05006404 · ClinicalTrials.gov registry record · NA

Autus Valve Pivotal Study

A NA study of Congenital Heart Disease, sponsored by Autus Valve Technologies.

Active
Registry status
NA
Development phase
51
Enrollment target
12
Study locations

NCT05006404: Active NA study of Congenital Heart Disease, sponsored by Autus Valve Technologies.

NCT05006404 is a NA study of Congenital Heart Disease that is active but no longer recruiting, run by Autus Valve Technologies. The registered enrollment target is 51 participants, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (89% lower). The trial reports 12 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05006404, a NA study of Congenital Heart Disease, is active but no longer recruiting, sponsored by Autus Valve Technologies.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
51 participants
Enrollment target
12
Study locations

Study Summary

Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years. The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.

Primary Outcome

Composite Endpoint: Freedom from a device-related complication through 30 days post-valve implantation as adjudicated by an independent Clinical Events Committee (CEC), including: * Death; * Valve thrombosis requiring intervention; * Symptomatic thromboembolism.

Conditions Studied

Interventions

  • DEVICE Pulmonary Valve Replacement Surgery

Study Locations (12)

California

  • Children's Hospital Los Angeles - Los Angeles

Colorado

  • Children's Hospital Colorado - Aurora

Georgia

  • Children's Healthcare of Atlanta - Atlanta

Illinois

  • Ann and Robert H. Lurie Children's Hospital of Chicago - Chicago

Massachusetts

  • Boston Children's Hospital - Boston

Michigan

  • University of Michigan - Mott Children's Hospital - Ann Arbor

New York

  • Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital - New York

North Carolina

  • Duke University - Durham

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2024-02-05
Est. Completion 2036-02-05
Phase NA
Autus Valve Technologies

1 total trials

What the registry record for NCT05006404 still lists

NCT05006404 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Congenital Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Pulmonary Valve Replacement Surgery is the first listed.

NCT05006404 lists 12 locations in 12 states (California, Colorado, Georgia).

Frequently Asked Questions

What is clinical trial NCT05006404 about?

NCT05006404 is a clinical study titled "Autus Valve Pivotal Study". Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects ...

What is the current status of trial NCT05006404?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 51 participants. The study started on 2024-02-05. Estimated completion is 2036-02-05.

What conditions does trial NCT05006404 study?

This clinical trial studies the following conditions: Congenital Heart Disease.

What interventions are being tested in trial NCT05006404?

The interventions under investigation include: Pulmonary Valve Replacement Surgery (DEVICE).

Who is sponsoring clinical trial NCT05006404?

This trial is sponsored by Autus Valve Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05006404 being conducted?

This trial has 12 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congenital Heart Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05006404's enrollment target sits among peer trials

51 39th of 63 higher than 24 of 63 other Congenital Heart Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Congenital Heart Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02701153 · 51 participants · NA

    Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

  • NCT03663790 · 51 participants · NA

    Effects of Gait Retraining on Lower Extremity Biomechanics

  • NCT03874052 · 51 participants · Phase 1

    Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • NCT04704661 · 51 participants · Phase 1

    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05006404, the US trial registry maintained by the National Library of Medicine. NCT05006404 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.